BioSyent (CVE:RX) Third Quarter 2024 Results
Key Financial Results
- Revenue: CA$9.56m (up 7.7% from 3Q 2023).
- Net income: CA$2.31m (down 1.8% from 3Q 2023).
- Profit margin: 24% (down from 27% in 3Q 2023). The decrease in margin was driven by higher expenses.
- EPS: CA$0.20 (in line with 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
BioSyent Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 6.2%. Earnings per share (EPS) also surpassed analyst estimates by 43%.
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company's shares are up 1.7% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 2 warning signs for BioSyent (1 is significant) you should be aware of.
If you're looking to trade BioSyent, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentValuation is complex, but we're here to simplify it.
Discover if BioSyent might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSXV:RX
BioSyent
Acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.
Flawless balance sheet with solid track record.
